MetaCap

OKYO Pharma Limited (OKYO)

NASDAQ: OKYOHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD

1.07-0.09 (-7.76%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

OKYO stock chart

Technical analysis

Key statistics

All statistics
Market cap
$56.15M
EPS (TTM)
-$0.24
52-week range
1.00 – 3.20
Day range
1.04 – 1.25
Volume / Avg
76.39K / 143.41K
Beta
—

52-week range

$1.00$3.20

OKYO stock today

OKYO Pharma (OKYO) closed at $1.07 on Nov 20, down 7.76% (-$0.09), versus the S&P 500's 3.70% decline. At this level, OKYO sits near the bottom of its 52-week range of $1.00 to $3.20: 66.6% below the high, set on Jan 14, 2026 and 7.0% above the low. OKYO is down 48.3% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 49.5%.

OKYO Pharma has posted a net loss over the last twelve months (EPS of -$0.24), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About OKYO Pharma

Company profile

OKYO Pharma Limited, a clinical-stage ophthalmology company, develops therapies for corneal and anterior diseases in the United Kingdom. Its lead clinical product candidate is urcosimod, which is in Phase 2 clinical trials for the treatment of dry eye disease and neuropathic corneal pain. The company is also developing OK-201 for the treatment of acute and chronic ocular pain.

Industry
Biotechnology: Biological Products (No Diagnostic Substances)
CEO
Mr. Robert J. Dempsey M.B.A.
Headquarters
London
Employees
5
IPO year
2022

Financial highlights

Full financials

OKYO Pharma reported a net loss of $4.7 million, compared with a loss of $16.8 million a year earlier. Diluted earnings per share came in at -$0.20.

OKYO Pharma annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue—————
Growth—————
Net income$-4.71M$-16.83M$-13.27M$-5.43M$-3.35M
EPS (diluted)$-0.20$-0.57$-0.61$-0.36$-0.32

Analyst forecast

Forecast

Consensus (3 analysts)

strong_buy

Avg. price target

$8.33+678.50%

  • Strong buy 1
  • Buy 2
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $5.00High $13.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

OKYO Pharma peers

Health Care sector
OKYO peer companies
CompanyPrice% ChgMarket capCompare
CGTXCognition Therapeutics Inc.0.5822-3.06%$55.37Mvs OKYO
CHRSCoherus Oncology Inc.0.3698-4.47%$57.15Mvs OKYO
AVXLAnavex Life Sciences Corp.0.5915-11.39%$54.83Mvs OKYO
CSBRChampions Oncology Inc.4.34-1.36%$60.41Mvs OKYO
NMRANeumora Therapeutics Inc.0.3339-3.78%$63.01Mvs OKYO
IMAImageneBio Inc.3.920.00%$48.83Mvs OKYO
ATRAAtara Biotherapeutics Inc.6.33-0.16%$64.49Mvs OKYO
TNYATenaya Therapeutics Inc.0.2866-3.99%$65.32Mvs OKYO

Indexes, lists and sector

OKYO Pharma stock FAQ

What is OKYO Pharma's stock price today?

OKYO last traded at $1.07 as of Nov 20, 4:00 PM EST, down 7.76% on the day. Prices are delayed at least 15 minutes.

Who is OKYO Pharma's CEO?

Mr. Robert J. Dempsey M.B.A. is the chief executive officer of OKYO Pharma Limited, which has about 5 employees.

What is the OKYO 52-week high?

The 52-week high for OKYO is $3.20 and the 52-week low is $1.00. The stock is currently 66.6% below its high.

Compare OKYO